TEYGLOA

Serial Number 98083601
602

Registration Progress

Application Filed
Jul 13, 2023
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

TEYGLOA

Basic Information

Serial Number
98083601
Filing Date
July 13, 2023
Abandonment Date
March 8, 2024
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Apr 1, 2024
Classes
005

Rights Holder

Amgen Inc.

03
Address
One Amgen Center Drive
Thousand Oaks, CA 913201799

Ownership History

Amgen Inc.

Original Applicant
03
Thousand Oaks, CA

Legal Representation

Attorney
Elsa D. Lemoine

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

8 events
Date Code Type Description Documents
Apr 1, 2024 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Apr 1, 2024 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Dec 7, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 7, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Dec 7, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Dec 5, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 13, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 17, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical preparations; pharmaceutical preparations and substances for use in the treatment of hematological, immune, autoimmune, inflammatory and respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system; pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005